New advances in tau imaging in parkinsonism

References

• Arai, T., Ikeda, K., Akiyama, H., Shikamoto, Y., Tsuchiya, K., Yagishita, S., … McGeer, P.L. (2001). Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick’s disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathologica, 101, 167–173.doi:10.1007/s004010000283
   PubMed Web of Science ®Google Scholar
• Armstrong, R.A., & Cairns, N.J. (2013). Spatial patterns of the tau pathology in progressive supranuclear palsy. Neurological Sciences, 34, 337–344. doi:10.1007/s10072-012-1006-0
   PubMed Web of Science ®Google Scholar
• Avila, J., Lucas, J., Perez, M., & Hernandez, F. (2004). Role of Tau protein in both physiological and pathological conditions. Physiological Reviews, 84, 361–384. doi:10.1152/physrev.00024.2003
   PubMed Web of Science ®Google Scholar
• Chien, D.T., Bahri, S., Szardenings, A.K., Walsh, J.C., Mu, F., Su, M.-Y., … Kolb, H.C. (2013). Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. Journal of Alzheimer’s Disease, 34, 457–468. doi:10.3233/JAD-122059
   PubMed Web of Science ®Google Scholar
• Chiotis, K., Saint-Aubert, L., Savitcheva, I., Jelic, V., Andersen, P., Jonasson, M., … Nordberg, A. (2016). Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm. European Journal of Nuclear Medicine and Molecular Imaging, 43, 1686–1699. doi:10.1007/s00259-016-3363-z
   PubMed Web of Science ®Google Scholar
• Cho, H., Choi, J.Y., Hwang, M.S., Lee, S.H., Ryu, Y.H., Lee, M.S., & Lyoo, C.H. (2017). Subcortical 18 F-AV-1451 binding patterns in progressive supranuclear palsy. Movement Disorders, 32, 134–140. doi:10.1002/mds.26844
   PubMed Web of Science ®Google Scholar
• Coakeley, S., Cho, S.S., Koshimori, Y., Rusjan, P., Harris, M., Ghadery, C., … Strafella, A.P. (2017). Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. Journal of Cerebral Blood Flow & Metabolism, 37, 3150–3160. doi:10.1177/0271678X16683695
   PubMed Web of Science ®Google Scholar
• Coakeley, S., & Strafella, A.P. (2015). Imaging pathological tau in atypical parkinsonian disorders. Current Opinion in Neurology, 28, 447–452. doi:10.1097/WCO.0000000000000210
   PubMed Web of Science ®Google Scholar
• Coakeley, S., & Strafella, A.P. (2017). Imaging tau pathology in parkinsonisms. NPJ Parkinson’s Disease, 3, 8. doi:10.1038/s41531-017-0023-3
   PubMed Web of Science ®Google Scholar
• Declercq, L., Rombouts, F., Koole, M., Fierens, K., Mariën, J., Langlois, X., … Bormans, G. (2017). Preclinical evaluation of (18)F-JNJ64349311, a novel PET Tracer for Tau imaging. The Journal of Nuclear Medicine, 58, 975–981. doi:10.2967/jnumed.116.185199
   PubMed Web of Science ®Google Scholar
• Dickerson, B., Domoto-Reilly, K., Hochberg, D., Brickhouse, M., Stepanovic, M., & Johnson, K. (2014). Imaging Tau pathology in vivo in FTLD: initial experience with [18F] T807 PET. Neurology, 82(10 Suppl), S8.007. doi:10.1016/j.jalz.2014.05.221
   Google Scholar
• Dickson, D. (1999). Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. Journal of Neurology, 246(Suppl 2), II6–I15. doi:10.1007/BF0316107610.1007/BF03161076
   PubMed Web of Science ®Google Scholar
• Eusebio, A., Koric, L., Félician, O., Guedj, E., Ceccaldi, M., & Azulay, J.-P. (2016). Progressive supranuclear palsy and corticobasal degeneration: Diagnostic challenges and clinicopathological considerations. Revue Neurologique, 172, 488–502. doi:10.1016/j.neurol.2016.07.009
   PubMed Web of Science ®Google Scholar
• Fawaz, M.V., Brooks, A.F., Rodnick, M.E., Carpenter, G.M., Shao, X., Desmond, T.J., … Scott, P.J.H. (2014). High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in alzheimer’s disease and progressive supranuclear palsy: Synthesis, preclinical evaluation, and lead selection. ACS Chemical Neuroscience, 5, 718–730. doi:10.1021/cn500103u
   PubMed Web of Science ®Google Scholar
• Fodero-Tavoletti, M.T., Furumoto, S., Taylor, L., Mclean, C.A., Mulligan, R.S., Birchall, I., … Villemagne, V.L. (2014). Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non – Alzheimer’s disease tauopathies. Alzheimer’s Research & Therapy, 6, 1–10. doi:10.1186/alzrt240
   PubMed Web of Science ®Google Scholar
• Gasparini, L., Terni, B., & Spillantini, M.G. (2007). Frontotemporal dementia with tau pathology. Neurodegener Dis, 4, 236–253. doi:10.1159/000101848
   PubMed Web of Science ®Google Scholar
• Grijalvo-Perez, A., & Litvan, I. (2014). Corticobasal degeneration. Seminars in Neurology, 34, 160–173. doi:10.1055/s-0034-1381734
   PubMed Web of Science ®Google Scholar
• Halliday, G., Bigio, E.H., Cairns, N.J., Neumann, M., MacKenzie, I.R.A., & Mann, D.M.A. (2012). Mechanisms of disease in frontotemporal lobar degeneration: Gain of function versus loss of function effects. Acta Neuropathologica, 124, 373–382. doi:10.1007/s00401-012-1030-4
   PubMed Web of Science ®Google Scholar
• Hammes, J., Bischof, G.N., Giehl, K., Faber, J., Drzezga, A., Klockgether, T., & van Eimeren, T. (2017). Elevated in vivo [18F]-AV-1451 uptake in a patient with progressive supranuclear palsy. Movement Disorders, 32, 170–171. doi:10.1002/mds.26727
   PubMedGoogle Scholar
• Hansen, A.K., Knudsen, K., Lillethorup, T.P., Landau, A.M., Parbo, P., Fedorova, T., … Borghammer, P. (2016). In vivo imaging of neuromelanin in Parkinson’s disease using 18F-AV-1451 PET. Brain, 139, 2039–2049. doi:10.1093/brain/aww098
   PubMed Web of Science ®Google Scholar
• Harada, A., Oguchi, K., Okabe, S., Kuno, J., Terada, S., Ohshima, T., … Hirokawa, N. (1994). Altered microtubule organization in small-calibre axons of mice lacking Tau protein. Nature, 369, 488–491. doi:10.1038/369488a0
   PubMed Web of Science ®Google Scholar
• Hashimoto, H., Kawamura, K., Igarashi, N., Takei, M., Fujishiro, T., Aihara, Y., … Zhang, M.-R. (2014). Radiosynthesis, photoisomerization, biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for imaging of Tau pathology. Journal of Nuclear Medicine, 55, 1532–1538. doi:10.2967/jnumed.114.139550
   PubMed Web of Science ®Google Scholar
• Höglinger, G.U., Respondek, G., Stamelou, M., Kurz, C., Josephs, K.A., Lang, A.E. … Movement Disorder Society-endorsed PSP Study Group. (2017). Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 32, 853–864. doi:10.1002/mds.26987
   PubMed Web of Science ®Google Scholar
• Ingram, E.M., & Spillantini, M.G. (2002). Tau gene mutations: Dissecting the pathogenesis of FTDP-17. Trends in Molecular Medicine, 8, 555–562. doi:10.1016/S1471-4914(02)02440-1
   PubMed Web of Science ®Google Scholar
• Ishiki, A., Harada, R., Okamura, N., Tomita, N., Rowe, C.C., Villemagne, V.L., … Furukawa, K. (2017). Tau imaging with [(18) F]THK-5351 in progressive supranuclear palsy. European Journal of Neurology, 24, 130–136. doi:10.1111/ene.13164
   PubMed Web of Science ®Google Scholar
• Josephs, K.A., Whitwell, J.L., Tacik, P., Duffy, J.R., Senjem, M.L., Tosakulwong, N., … Murray, M.E. (2016). [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathologica, 132, 931–933. doi:10.1007/s00401-016-1618-1
   PubMed Web of Science ®Google Scholar
• Kepe, V., Bordelon, Y., Boxer, A., Huang, S.-C., Liu, J., Thiede, F.C., … Barrio, J.R. (2013). PET imaging of neuropathology in tauopathies: Progressive supranuclear palsy. Journal of Alzheimer’s Disease, 36, 145–153. doi:10.3233/JAD-130032
   PubMed Web of Science ®Google Scholar
• Kikuchi, A., Okamura, N., Hasegawa, T., Harada, R., Watanuki, S., Funaki, Y., … Aoki, M. (2016). In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET. Neurology, 87, 2309–2316. doi:10.1212/WNL.0000000000003375
   PubMed Web of Science ®Google Scholar
• Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R., … Zee, D. (1996). Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP International Workshop. Neurology, 47, 1–9.
   PubMed Web of Science ®Google Scholar
• Lowe, V.J., Curran, G., Fang, P., Liesinger, A.M., Josephs, K.A., Parisi, J.E., … Murray, M.E. (2016). An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathologica Communications, 4, 58. doi:10.1186/s40478-016-0315-6
   PubMed Web of Science ®Google Scholar
• Marquié, M., Normandin, M.D., Meltzer, A.C., Siao Tick Chong, M., Andrea, N.V., Antón-Fernández, A., … Gómez-Isla, T. (2017). Pathological correlations of [F-18]-AV-1451 imaging in non-Alzheimer tauopathies. Annals of Neurology, 81, 117–128. doi:10.1002/ana.24844
   PubMed Web of Science ®Google Scholar
• Marquié, M., Normandin, M.D., Vanderburg, C.R., Costantino, I.M., Bien, E.A., Rycyna, L.G., … Gómez-Isla, T. (2015). Validating novel Tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Annals of Neurology, 78, 787–800. doi:10.1002/ana.24517
   PubMed Web of Science ®Google Scholar
• Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., … Higuchi, M. (2013). Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron, 79, 1094–1108. doi:10.1016/j.neuron.2013.07.037
   PubMed Web of Science ®Google Scholar
• Mathis, C.A., & Klunk, W.E. (2013). Imaging Tau deposits in vivo: Progress in viewing more of the proteopathy picture. Neuron, 79, 1035–1037. doi:10.1016/j.neuron.2013.09.001
   PubMed Web of Science ®Google Scholar
• McMillan, C.T., Irwin, D.J., Avants, B.B., Powers, J., Cook, P.A., Toledo, J.B., … Grossman, M. (2013). White matter imaging helps dissociate Tau from TDP-43 in frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery, and Psychiatry, 84, 949–955. doi:10.1136/jnnp-2012-304418
   PubMed Web of Science ®Google Scholar
• McMillan, C.T., Irwin, D.J., Nasrallah, I., Phillips, J.S., Spindler, M., Rascovsky, K., … Grossman, M. (2016). Multimodal evaluation demonstrates in vivo (18)F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration. Acta Neuropathologica, 132, 935–937. doi:10.1007/s00401-016-1640-3
   PubMed Web of Science ®Google Scholar
• Ng, K.P., Pascoal, T.A., Mathotaarachchi, S., Therriault, J., Kang, M.S., Shin, M., … Rosa-Neto, P. (2017). Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimer’s Research & Therapy, 9, 25. doi:10.1186/s13195-017-0253-y
   PubMed Web of Science ®Google Scholar
• Noble, W., Diane, P., Miller, C.C.J., Lovestone, S., Noble, W., & Diane, P. (2013). The importance of tau phosphorylation for neurodegenerative diseases. Frontiers in Neurology, 4, 83. doi:10.3389/fneur.2013.00083
   PubMed Web of Science ®Google Scholar
• Ono, M., Sahara, N., Kumata, K., Ji, B., Ni, R., Koga, S., … Higuchi, M. (2017). Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain, 140, aww339. doi:10.1093/brain/aww339
   Web of Science ®Google Scholar
• Passamonti, L., Vázquez Rodríguez, P., Hong, Y.T., Allinson, K.S.J., Williamson, D., Borchert, R.J., … Rowe, J.B. (2017). 18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy. Brain, 140, aww340. doi:10.1093/brain/aww340
   Web of Science ®Google Scholar
• Perez-Soriano, A., Arena, J.E., Dinelle, K., Miao, Q., Mckenzie, J., Neilson, N., … Shinotoh, H. (2017). PBB3 imaging in parkinsonian disorders: Evidence for binding to Tau and other proteins. Movement Disorders, 29, 431–434. doi:10.1002/mds.27029
   Google Scholar
• Rabinovici, G., & Miller, B. (2010). Frontotemporal lobar degeneration. CNS Drugs, 24, 375–398. doi:10.1016/j.ncl.2007.03.005
   PubMed Web of Science ®Google Scholar
• Saeed, U., Compagnone, J., Aviv, R.I., Strafella, A.P., Black, S.E., Lang, A.E., & Masellis, M. (2017). Imaging biomarkers in Parkinson’s disease and parkinsonian syndromes: Current and emerging concepts. Translational Neurodegeneration, 6, 8. doi:10.1186/s40035-017-0076-6
   PubMed Web of Science ®Google Scholar
• Sander, K., Lashley, T., Gami, P., Gendron, T., Lythgoe, M.F., Rohrer, J.D., … Årstad, E. (2016). Characterization of Tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer’s disease, primary tauopathies, and other dementias. Alzheimer’s & Dementia, 12, 1116–1124. doi:10.1016/j.jalz.2016.01.003
   PubMed Web of Science ®Google Scholar
• Shah, M., & Catafau, A.M. (2014). Molecular imaging insights into neurodegeneration: Focus on Tau PET radiotracers. Journal of Nuclear Medicine, 55, 871–875. doi:10.2967/jnumed.113.136069
   PubMed Web of Science ®Google Scholar
• Shahani, N., & Brandt, R. (2002). Cellular and molecular life sciences functions and malfunctions of the Tau proteins. Cellular and Molecular Life Sciences, 59, 1668–1680.doi:10.1007/PL00012495
   PubMed Web of Science ®Google Scholar
• Shinotoh, H., Shimada, H., Hirano, S., Furukawa, S., Eguchi, Y., Takahata, K., … Higuchi, M. (2014). Imaging of tau pathology in patients with non-Alzheimer’s disease tauopathies by [11C]PBB3-PET. Alzheimer’s & Dementia, 10, P6–P7. doi:10.1016/j.jalz.2014.04.030
   Google Scholar
• Shoghi-Jadid, K., Small, G.W., Agdeppa, E.D., Kepe, V., Ercoli, L.M., Siddarth, P., … Barrio, J.R. (2002). Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. The American Journal of Geriatric Psychiatry, 10, 24–35.
   PubMed Web of Science ®Google Scholar
• Smith, R., Puschmann, A., Schöll, M., Ohlsson, T., van Swieten, J., Honer, M., … Hansson, O. (2016). 18F-AV-1451 Tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain, 139, 2372–2379. doi:10.1093/brain/aww163
   PubMed Web of Science ®Google Scholar
• Smith, R., Schain, M., Nilsson, C., Strandberg, O., Olsson, T., Hägerström, D., … Hansson, O. (2017). Increased basal ganglia binding of 18 F-AV-1451 in patients with progressive supranuclear palsy. Movement Disorders, 32, 108–114. doi:10.1002/mds.26813
   PubMed Web of Science ®Google Scholar
• Spillantini, M.G., Bird, T.D., & Ghetti, B. (1998). Frontotemporal dementia and parkinsonism linked to chromosome 17: A new group of tauopathies. Brain Pathology, 8, 387–402. doi:10.1111/j.1750-3639.1998.tb00162.x
   PubMed Web of Science ®Google Scholar
• Spillantini, M.G., & Goedert, M. (2013). Tau pathology and neurodegeneration. The Lancet Neurology, 12, 609–622. doi:10.1016/S1474-4422(13)70090-5
   PubMed Web of Science ®Google Scholar
• Spina, S., Schonhaut, D.R., Boeve, B.F., Seeley, W.W., Ossenkoppele, R., O’neil, J.P., … Rabinovici, G.D. (2017). Frontotemporal dementia with the V337M MAPT mutation: Tau-PET and pathology correlations. Neurology, 88, 758–766. doi:10.1212/WNL.0000000000003636
   PubMed Web of Science ®Google Scholar
• Stamelou, M., & Hoeglinger, G.U. (2013). Atypical parkinsonism: An update. Current Opinion in Neurology, 26, 401–405. doi:10.1097/WCO.0b013e3283632da6
   PubMed Web of Science ®Google Scholar
• Steele, J.C., Richardson, J.C., & Olszewski, J. (1964). Progressive supranuclear palsy: A heterogeneous degeneration involving the brain stem, Basal Ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Archives of Neurology, 10, 333–359.doi:10.1001/archneur.1964.00460160003001
   PubMed Web of Science ®Google Scholar
• Suhara, T., Shimada, H., Shinotoh, H., Hirano, S., Eguchi, Y., Takahata, K., … Higuchi, M. (2014). In vivo tau PET imaging using [11C] PBB3 in Alzheimer’s disease and non-Alzheimer’s disease tauopathies. The Journal of Nuclear Medicine, 55, 11–12.
   Web of Science ®Google Scholar
• Takahashi, M., Weidenheim, K.M., Dickson, D.W., & Ksiezak-Reding, H. (2002). Morphological and biochemical correlations of abnormal tau filaments in progressive supranuclear palsy. Journal of Neuropathology and Experimental Neurology, 61, 33–45.doi:10.1093/jnen/61.1.33
   PubMed Web of Science ®Google Scholar
• Vermeiren, C., Mercier, J., Viot, D., Mairet-Coello, G., Hannestad, J., Courade, J.-P., … Gillard, M. (2015). T807, a reported selective tau tracer, binds with nanomolar affinity to monoamine oxidase a. Alzheimer’s & Dementia, 11, P283. doi:10.1016/j.jalz.2015.07.381
   Google Scholar
• Verny, M., Duyckaerts, C., Agid, Y., & Hauw, J.-J. (1996). The significance of cortical pathology in progressive supranuclear palsy. Brain, 119, 1123–1136. doi:10.1093/brain/119.4.1123
   PubMed Web of Science ®Google Scholar
• Verny, M., Jellinger, K.A., Hauw, J.-J., Bancher, C., Litvan, I., & Agid, Y. (1996). Progressive supranuclear palsy: A clinicopathological study of 21 cases. Acta Neuropathologica, 91, 427–431. doi:10.1007/s004010050446
   PubMed Web of Science ®Google Scholar
• Whitwell, J.L., Lowe, V.J., Tosakulwong, N., Weigand, S.D., Senjem, M.L., Schwarz, C.G., … Josephs, K.A. (2017). [18F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. Movement Disorders, 32, 124–133. doi:10.1002/mds.26834
   PubMed Web of Science ®Google Scholar
• Williams, D.R., & Lees, A.J. (2010). What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)? Movement Disorders, 25, 357–362. doi:10.1002/mds.22977
   PubMed Web of Science ®Google Scholar
• Williams, D.R., De Silva, R., Paviour, D.C., Pittman, A., Watt, H.C., … Ees, A.J. (2005). Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain, 128, 1247–1258. doi:10.1093/brain/awh488
   PubMed Web of Science ®Google Scholar
• Xia, C.-F., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L.F., Kasi, D., … Kolb, H.C. (2013). [18F]T807, a novel Tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimer’s & Dementia, 9, 666–676. doi:10.1016/j.jalz.2012.11.008
   PubMed Web of Science ®Google Scholar
• Zhukareva, V., Joyce, S., Schuck, T., Van Deerlin, V., Hurtig, H., Albin, R., … Lee, V.M.Y. (2006). Unexpected abundance of pathological Tau in progressive supranuclear palsy white matter. Annals of Neurology, 60, 335–345. doi:10.1002/ana.20916
   PubMed Web of Science ®Google Scholar